Larix A/S Licenses OmniComm Systems' eClinical Solutions
Larix A/S Licenses OmniComm Systems' eClinical Solutions
FORT LAUDERDALE, Fla., July 2, 2012 (GLOBE NEWSWIRE) – OmniComm Systems, Inc (OTCBB:OMCM), announced that it has signed an agreement with Larix A/S to support their clinical research needs for a 5 year, 31 site study.
Larix, a full-service Clinical Research Organization (CRO) in Denmark offering assistance in all aspects of clinical trials, provides services within statistics, Data Management (DM), Clinical Research (CR), Pharmacovigilance (PV) and Data Monitoring Committees (DMCs) to pharmaceutical, biotechnology and medical device companies. This partnership will enable Larix to provide their customers with high quality products and services to manage complex clinical trials. Larix will utilize OmniComm's fully integrated eClinical suite, including Portal, Electronic Data Capture (EDC), and Clinical Data Management System (CDMS).
"Larix was looking for a system which could support paper, EDC and hybrid studies and which could live up to Larix's quality standards to ensure compliance with regulatory requirements. Furthermore, we wanted a solution that was attractive both from a user's point of view and from a cost point of view. We looked at several solutions but decided in the end to go with OmniComm's eClinical Suite. We believe that the system is flexible and easy to use. We are pleased with this collaboration between Larix and OmniComm." said Klaus Juel Olsen, CEO.
"We are pleased to have been chosen by this prestigious family founded CRO." said Stephen Johnson, President and COO of OmniComm. "They've become one of the largest Danish CROs based on their strong reputation for good customer service, and we look forward to partnering with them to build on their reputation for providing quality solutions and services."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
